{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Dr. Paika Podcast","title":"5 Things You Should NEVER Do on Wegovy, Ozempic & Zepbound","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/329ab5d1\"></iframe>","width":"100%","height":180,"duration":862,"description":"#Ozempic #Wegovy #Zepbound #GLP1 #weightlossjourney \nAre you taking Wegovy, Ozempic, or Zepbound and feeling like your results have stalled? In this video, board-certified physician Dr. Mohammed Paika breaks down the 5 mistakes that quietly sabotage GLP-1 results — and exactly what to do instead to keep losing fat, protect your muscle, and avoid unnecessary side effects.\nDrawing on his experience as a hospitalist and obesity medicine specialist, Dr. Paika walks through dose titration, nutrition, digestion, and lab work — the pieces most people never get told about.\nTIMESTAMPS:\n0:00 Intro — Why Your Results Might Be Stalling\n0:53 Meet Dr. Paika\n1:37 Mistake #1: Chasing the Calendar Instead of Your Biology\n4:07 Mistake #2: Treating the Medication Like It Replaces the Basics\n6:02 Mistake #3: Eating Too Little (and Losing the Wrong Weight)\n8:29 Mistake #4: Ignoring What Your Gut Is Telling You\n10:47 Mistake #5: Never Checking Your Blood Work\n12:27 Final Thoughts + What to Watch Next\nREFERENCES:\n1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.\n2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.\n3. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27:740-756.\n4. Taheri S, et al. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased BMI. PLoS Med. 2004;1(3):e62.\n5. Wolfe RR. The underappreciated role of muscle in health and disease. Am J Clin Nutr. 2006;84:475-482.\n6. Longland TM, et al. Higher dietary protein during an energy deficit promotes greater lean mass gain and fat loss. Am J Clin Nutr. 2016;103:738-746.\n7. Holst JJ. The physiology of glucagon-like peptide-1. Physiol Rev. 2007;87:1409-1439.\n8. Monami M, et al. Safety issues with GLP-1 receptor agonists (pancreatitis, pancreatic cancer, cholelithiasis). Diabetes Obes Metab. 2017;19(9):1233-1241.\n9....","thumbnail_url":"https://img.transistorcdn.com/9qIr9DvwV8ODN3d9cHtpN76KWo0AHFHUFFi87mNWtws/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lNGNl/MTliYWE0MmYyMTY1/NWNjZTA2MWU0Zjgx/N2I5YS5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}